Department of Biomaterials and Tissue Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Regenerative Medicine Group (REMED), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Stem Cell Rev Rep. 2021 Feb;17(1):193-213. doi: 10.1007/s12015-020-10110-w. Epub 2021 Jan 28.
Currently, there are no specific and efficient vaccines or drugs for COVID-19, particularly in severe cases. A wide range of variations in the clinical symptoms of different patients attributed to genomic differences. Therefore, personalized treatments seem to play a critical role in improving these symptoms and even similar conditions. Prompted by the uncertainties in the area of COVID-19 therapies, we reviewed the published papers and concepts to gather and provide useful information to clinicians and researchers interested in personalized medicine and cell-based therapy. One novel aspect of this study focuses on the potential application of personalized medicine in treating severe cases of COVID-19. However, it is theoretical, as any real-world examples of the use of genuinely personalized medicine have not existed yet. Nevertheless, we know that stem cells, especially MSCs, have immune-modulatory effects and can be stored for future personalized medicine applications. This theory has been conjugated with some evidence that we review in the present study. Besides, we discuss the importance of personalized medicine and its possible aspects in COVID-19 treatment, then review the cell-based therapy studies for COVID-19 with a particular focus on stem cell-based therapies as a primary personalized tool medicine. However, the idea of cell-based therapy has not been accepted by several scientific communities due to some concerns of lack of satisfactory clinical studies; still, the MSCs and their clinical outcomes have been revealed the safety and potency of this therapeutic approach in several diseases, especially in the immune-mediated inflammatory diseases and some incurable diseases. Promising outcomes have resulted in that clinical studies are going to continue.
目前,针对 COVID-19,特别是重症病例,还没有特定的高效疫苗或药物。由于基因组差异,不同患者的临床症状存在广泛的变异。因此,个性化治疗似乎在改善这些症状甚至类似情况下发挥着关键作用。鉴于 COVID-19 治疗领域的不确定性,我们回顾了已发表的论文和概念,以收集和为对个性化医学和基于细胞的治疗感兴趣的临床医生和研究人员提供有用的信息。本研究的一个新颖之处在于关注个性化医学在治疗 COVID-19 重症病例中的潜在应用。然而,这只是理论上的,因为目前还没有真正个性化医学应用的实际例子。尽管如此,我们知道干细胞,特别是间充质干细胞,具有免疫调节作用,可以储存起来以备将来用于个性化医学应用。这一理论与我们在本研究中回顾的一些证据相结合。此外,我们讨论了个性化医学的重要性及其在 COVID-19 治疗中的可能方面,然后回顾了针对 COVID-19 的基于细胞的治疗研究,特别关注干细胞为主要个性化治疗工具的治疗。然而,由于缺乏令人满意的临床研究的一些担忧,基于细胞的治疗的想法尚未被几个科学界所接受;尽管如此,间充质干细胞及其临床结果已经揭示了这种治疗方法在几种疾病中的安全性和有效性,特别是在免疫介导的炎症性疾病和一些无法治愈的疾病中。有希望的结果导致了正在进行的临床研究。